Neurologic outcomes of toxic oil syndrome patients 18 years after the epidemic by Posada de la Paz, Manuel et al.
Toxic oil syndrome (TOS) appeared as a new
disease in Spain in 1981. TOS continues to be
of great interest to epidemiologists and toxicol-
ogists because it is an example of the potential
risks of adulterated food, as well as showing
the importance of chemical environmental
exposures in the development of autoimmune
diseases (Gelpi et al. 2002). Although TOS
patients have a mortality rate similar to that of
the Spanish population as a whole, many sur-
vivors have been left with a variety of handi-
capping conditions (Gomez et al. 1998). The
numerous social, clinical, and research prob-
lems dealt with during this epidemic have
provided a basis for the study of other similar
episodes, such as the eosinophilia-myalgia
syndrome (EMS) epidemic (Kilbourne 1992),
and other recent important problems in food
processing and sales, such as new-variant
Creutzfeld-Jacob disease (Tyler 2003) and the
recent episode of contaminated chicken in
Belgium (Van Larebeke et al. 2001).
The first case of the TOS epidemic was
reported on 1 May 1981 in Torrejón de Ardoz,
Province of Madrid (Tabuenca 1981). TOS
resulted from the consumption of rapeseed oil
that had been denatured with 2% aniline
under the pretext that it was for industrial use;
the oil had been refined in an attempt to
remove the aniline and then illicitly sold as
pure olive oil for human consumption
(Tabuenca 1981). High temperatures and
extreme vacuum conditions during the refin-
ing process led to a reaction of the aniline
with fatty acids and tryglicerides, which are
basic in regular oils, producing two different
new families of compounds: fatty acid anilides
and esters of the phenyl amino propanediol.
More than 100 different compounds from
these two families have been described in these
oils, and their toxicologic mechanisms are still
not well known (Gelpi et al. 2002; Posada de
la Paz et al. 2001).
During the first month of the epidemic,
about 10,000 persons became ill, and by the
time the official patient registry closed, it con-
tained the names of more than 20,000 persons
who were affected by TOS. TOS developed
in three clinically distinct phases now referred
to as acute, intermediate, and chronic
(Abaitua Borda and Posada de la Paz 1991;
Posada de la Paz et al. 2001). The acute phase
was characterized by noncardiogenic pul-
monary edema with dyspnea, headaches, asthe-
nia, itchy scalp, rash, abdominal pain, fever,
and eosinophilia. Severe myalgias and muscle
cramps marked the end of the acute phase.
After the first 2 months of illness, patients
typically entered an intermediate phase, lasting
about 2 months. This phase was characterized
by frequent changes in signs and symptoms.
Clinical features frequently observed included
sensory neuropathy in 55% of patients and
intense myalgia in 47.4%. Other findings
were dysphagia, pulmonary hypertension,
thromboembolic phenomena of the large ves-
sels in 1.8% of the patients, marked weight
loss, hepatic cholestasis, and induration of the
skin followed by skin infiltration. High levels
of peripheral blood eosinophils, hyperglycemia,
and elevated triglycerides and cholesterol were
also observed.
Around 59% of TOS patients progressed
to a chronic phase with features of sclero-
derma, motor and sensory polyneuropathy,
carpal tunnel syndrome, joint contractures,
myalgias, and muscle cramps. Cognitive
symptoms, such as memory loss and depres-
sion, have also been reported during the
chronic phase of TOS (Abaitua Borda and
Posada de la Paz 1991).
Since the end of the 1980s, most patients
have experienced remission of the main clinical
features, but some patients still show substan-
tial neurologic sequelae such as myalgias,
cramps, and contractures, and many continue
to complain of other symptoms that may be of
neurologic origin (Abaitua Borda and Posada
de la Paz 1991). Often these patients’ com-
plaints have been vague or difficult to assess,
and some have been mistakenly interpreted as
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Toxic oil syndrome (TOS) resulted from consumption of rapeseed oil denatured with 2% aniline
and affected more than 20,000 persons. Eighteen years after the epidemic, many patients continue
to report neurologic symptoms that are difficult to evaluate using conventional techniques. We
conducted an epidemiologic study to determine whether an exposure to toxic oil 18 years ago was
associated with current adverse neurobehavioral effects. We studied a case group of 80 adults
exposed to toxic oil 18 years ago and a referent group of 79 adult age- and sex-frequency–matched
unexposed subjects. We interviewed subjects for demographics, health status, exposures to neuro-
toxicants, and responses to the Kaufman Brief Intelligence Test (K-BIT), Programa Integrado de
Exploracion Neuropsicologica (PIEN), and Goldberg depression questionnaires and administered
quantitative neurobehavioral and neurophysiologic tests by computer or trained nurses. The
groups did not differ with respect to educational background or other critical variables. We exam-
ined associations between case and referent groups and the neurobehavioral and neurophysiologic
outcomes of interest. Decreased distal strength of the dominant and nondominant hands and
increased vibrotactile thresholds of the fingers and toes were significantly associated with exposure
to toxic oil. Finger tapping, simple reaction time latency, sequence B latency, symbol digit latency,
and auditory digit span were also significantly associated with exposure. Case subjects also had sta-
tistically significantly more neuropsychologic symptoms compared with referents. Using quantita-
tive neurologic tests, we found significant adverse central and peripheral neurologic effects in a
group of TOS patients 18 years after exposure to toxic oil when compared with a nonexposed ref-
erent group. These effects were not documented by standard clinical examination and were found
more frequently in women. Key words: case–referent study, environmental food epidemic, exam,
long-term effects, neurobehavioral tests, toxic oil syndrome. Environ Health Perspect
111:1326–1334 (2003). doi:10.1289/ehp.6098 available via http://dx.doi.org/ [Online 9 April 2003]
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fictitious or exaggerated. As a result, some
TOS patients may have been incorrectly classi-
fied as “chronic complainers,” when instead
they suffer from a genuine neurologic disorder.
A study that used the Nottingham Self-
perceived Health Profile to evaluate a sub-
cohort of TOS patients found that, as a group,
TOS patients felt that they were in very poor
health and that they suffered from a number
of health problems (Gomez et al. 1998).
Although neurologic findings may be diffi-
cult to quantify, within the last few years tech-
niques have been developed to measure
neurologic abnormalities more accurately (Gerr
et al. 1990, 1991; Letz 1991). Quantitative
neurologic testing has been successfully used to
characterize other diseases with subtle neuro-
logic findings, such as the epidemic of optic
and peripheral neuropathy that occurred in
Cuba (Cuba Neuropathy Field Investigation
Team 1995); EMS, a disease clinically similar
to TOS (Philen and Posada 1993; Sullivan et
al. 1996); and other diseases related to toxic
environmental exposures (Stokes et al. 1998).
The hypothesis of this study was that
TOS patients who have central or peripheral
neurologic symptoms, which may be difficult
to relate to specific neurologic findings on
clinical examination, have neurologic abnor-
malities that can be identified and measured
objectively using quantitative neurologic test-
ing and can be compared with a referent
group from the same geographic area. We
compared the results of analogous items on
the clinical neurologic examination with those
of the quantitative neurologic examination in
TOS patients. These data were used to deter-
mine which quantitative examinations yielded
more information than the clinical neurologic
examination, as well as to guide future deci-
sions on the use of the quantitative neurologic
examination in the TOS cohort.
Materials and Methods
We used a case–referent study design to assess
the possible neurologic pathology in TOS
patients.
Subjects
Setting. All TOS case participants and healthy
referent participants were chosen from the
Alcorcón locality in the southern part of the
Madrid province, one of the areas affected by
TOS in 1981, with 1,400 registered patients.
All interviewing, testing, and other parts of
the study were performed in the Hospital
Fundación Alcorcón, Alcorcón (Madrid
Province, Spain).
Sampling. We used a simple random sam-
ple of the TOS patients who were registered in
Alcorcón at the time the official TOS census
was done. Each TOS patient who was known
to be living in the Alcorcón area was assigned a
random number, and those random numbers
were then sorted in ascending order. Patients
were then contacted in numerical order until
our sample size of 80 TOS patients was
reached. The referent group was recruited from
friends or family members living in the same
geographic area. The case (exposed) group con-
sisted of 80 adults who had been exposed to
toxic oil 18 years ago, who had developed a
clinical case of TOS, and who were then fre-
quency-matched for age (± 5 years) and sex to
a referent (unexposed) group of 79 adults.
Participants selected as the reference popula-
tion were required to report being free of signs
of illness, although they could have had the
same probability of being exposed as the cases.
Case definition. All TOS case patient par-
ticipants were required a) to be registered in
the 1985 TOS patient registry and in the
REVCEN (acronym of the Spanish “revision
of the census,” the official TOS morbidity
registry containing clinical information from
1981 to 1988) (Kilbourne et al. 1992); b) to
have lived in Madrid Province, Alcorcón
locality, in 1981 at the time of developing
TOS; and c) to reside in Madrid Province,
Alcorcón locality, during 1998–1999 (the
time period when participants were enrolled
and clinical and quantitative neurologic
examinations were performed). In addition,
participants had to be ≤ 65 years of age at the
time the study was conducted.
Exclusions. TOS patients were selected
among those living in Alcorcón during the
epidemic onset, but one of the conditions for
entering the study was to live in Alcorcón at
the beginning of the study. Participants with
diagnoses other than TOS that can result in
neuropathy, including diabetes; renal disease;
cerebrovascular accidents; alcoholism; or
head, spinal cord, or other neurologic trauma,
were excluded from the study. Pregnant
women, persons unable to consent, and those
unable to physically collaborate with the test-
ing requirements were excluded (Table 1).
On the other hand, selection of the referent
group was made starting from cases. It was
imperative that this group had previously ful-
filled the same exclusion criteria as the cases.
Additionally, a few participants were excluded
from a particular test because of problems
specific to that examination (i.e., participants
with trauma or other injury to the hand or
arm who were unable to complete motor
strength measurements).
Recruitment. A meeting was held with the
local TOS patient association in Alcorcón,
informing the members of the objectives of
the study and seeking their participation.
Subsequently, all potential study participants
were contacted via the local TOS patient
association, first via a letter requesting their
participation, followed by a phone call to
schedule an interview. TOS patients thus
contacted were interviewed in person and
requested to participate, and signed a consent
form at the time of the interview.
Data Collection 
Questionnaires. A questionnaire was adminis-
tered by a trained interviewer to each partici-
pant. Neurologic signs and symptoms, history
of neurologic disorders, occupational and envi-
ronmental exposure histories, residential his-
tory, medication use, dietary factors, smoking,
alcohol use, and other exposure information
were assessed for all participants and, if appro-
priate, adjusted for in the analysis. Information
on demographics, past and current health, past
exposures to neurotoxicants, and responses to
the Goldberg Depression Inventory (Spanish
translation) (Montón et al. 1993) were also
collected by personal interview.
Neurologic examination. All participants
were examined by one of two neurologists
from Hospital Fundación Alcorcón, both of
whom have extensive experience in TOS
patient care, with special attention given to
signs and symptoms of TOS and its related
neurologic findings. Results were recorded in
a standardized form.
Neurobehavioral tests. Medical testing
consisted of a battery of neurobehavioral tests
used to determine the functional status of the
central nervous system (CNS), the peripheral
nervous system (PNS), and the autonomic
nervous system (ANS). These tests were
administered by computer with the help of
specially trained nurses. Detailed descriptions
of how to perform these tests have been pub-
lished elsewhere (Baker et al. 1985; Gerr et al.
1990, 1991; Letz 1991).
Vibrotactile threshold testing. Cutaneous
vibrotactile thresholds were obtained for both
index fingers and great toes using a portable
vibrometer (Vibratron II; Physitemp, Inc.,
Clifton, NJ, USA) producing sinusoidal oscil-
lation at 100 Hz. The results are reported in
log10 micrometers of vibration amplitude.
The “method of limits” protocol used has
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Table 1. Reasons for nonparticipation of TOS patients
in the study of long-term neurologic outcomes of
TOS patients, Madrid, Spain, 1999.
Cause/refusal No.a
Did not fulfill inclusion criteria
No longer live in Alcorcón 6
Death 2
Diagnosed with diabetes 2
Pregnancy 1
Down syndrome 1




Non-TOS medical reason 4
Family responsibilities 3
Denied TOS 1
aTOS patients contacted, 160; nonparticipants, 80; total
TOS participants, 80.
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been shown to be reliable and time efficient
(Gerr et al. 1990; Gerr and Letz 1988, 1993).
Higher values indicate poorer sensory func-
tion. The vibrotactile threshold is a very useful
measure for assessment of large, myelinated
nerve fiber function, the fiber type most
commonly affected by toxic exposures,
including TOS. For a toxic axonal neuropa-
thy, the lower extremities are likely to be
more substantially affected than the upper
extremities, although in this study some toxic
effects were measured in both the upper and
lower extremities.
Hand strength dynamometry. Bilateral
hand strength dynamometry was performed
on all study participants to assess neuro-
muscular function. Grip strength and pinch
strength were measured by means of an
adjustable-handle Jamar dynamometer and a
B&L pinch gauge (Asimow Engineering
Company, Santa Monica, CA, USA), using
the method and instructions of Mathiowetz
et al. (1984).
Standing steadiness testing. Standing sta-
bility was measured using a standard, commer-
cially available force platform (AccuSway
Platform; Advanced Mechanical Technologies,
Inc., Waltham, MA, USA). Timing and data
recording were accomplished by a dedicated
IBM-PC–compatible laptop computer. The
method used for measurement of standing
stability has been described previously (Letz
and Gerr 1995). Subjects, in stocking feet,
were asked to stand as still as possible on the
platform with hands at their sides either while
fixating visually on a 2-cm-diameter circular
mark on the wall, or with eyelids closed.
Three trials with eyes open and three trials
with eyes closed, 25 sec each, were alternated.
The primary outcome variable analyzed was
mean sway speed in centimeters per second
(equivalent to the total length of the sway
path divided by 25) averaged over the three
eyes-closed trials.
Heart rate variability. Heart rate variability
was obtained by measuring the interval, in mil-
liseconds, between successive R-waves of the
electrocardiogram. Surface electrodes were
placed on the wrists and leg of the study partic-
ipant. A differential amplifier (DAM-50;
World Precision Instruments, Sarasota, FL,
USA) and an IBM-compatible personal com-
puter equipped with an analog-to-digital con-
verter (Microstar Laboratories, Portland, OR,
USA) were used for processing of the electro-
cardiogram signal. We created custom software
to capture and store the interval between suc-
cessive R-waves of the digitized signal. The pri-
mary outcome of this measure is the coefficient
of variation during rest and the coefficient of
variation during a period of deep breathing.
Other variables explored included change in
heart rate between resting and deep breathing
and change in the coefficient of variation
between resting and deep breathing (Murata
and Araki 1991).
CNS testing. Tests of CNS function were
a combination of a few manually administered
neuropsychologic tests and a selection of 
computer-administered tests from NES2
(Baker et al. 1985) and NES3 (Baker et al.
1988; Letz et al. 1996). Motor tests were
emphasized, with a sampling of other impor-
tant CNS functions. The tests administered
are described briefly below. Total administra-
tion time for all of these CNS tests was
approximately 60 min. The NES2 tests
(Version 4.75) were administered on a
Toshiba 3200Sx computer (Toshiba America
Electronic Components, Irvine, CA, USA)
with an NES2 joystick, and the NES3 tests
(Version 1.02) (Baker et al. 1985; Letz 1991)
were administered on a Fujitsu Point 510 pen-
based computer (Toshiba America Electronic
Components) with external audio speakers. 
In the grooved pegboard test, the subject
must place 25 notched pegs into a board with
25 matching holes. The time taken to insert
all 25 pegs is recorded for dominant and non-
dominant hands. The finger-tapping test
measures motor quickness and coordination.
The participant presses a button as many
times as possible within 30-sec trials. After a
practice trial, one trial each is performed with
the preferred hand, the nonpreferred hand,
and both hands alternating. The hand–eye
coordination test evaluates manual dexterity
and coordination. The participant uses a joy-
stick to trace a large sine wave pattern on the
video display. Vertical deviation from the wave
pattern is recorded (as root mean squared
error). Five trials are given; the mean of the
two best trials is used as the summary measure.
The simple reaction time test measures motor
speed and sustained attention. The subject
presses a joystick button as quickly as possible
after a large square appears in the middle of the
computer screen. Fifty trials are administered,
and the preferred summary measure is the
mean reaction time of the last 40 trials.
Several tests measured cognitive functions.
The digit symbol test is a modification of the
Digit-Symbol Substitution test from the
Wechsler Adult Intelligence Scale–Revised
(Letz et al. 1996). It measures coding skills,
attention, and concentration. Symbols are
matched with the digits 1 through 9 in a “key”
at the top of the screen, and the participant
must indicate which of the symbols in scram-
bled order at the bottom of the screen is
matched with a test stimulus presented in the
middle of the screen. The response latencies
for completing three sets of nine pairs are
recorded, and the preferred summary measure
is the total time to complete the 27 stimuli. 
The sequences test is similar to the stan-
dard Trial-Making Test (Letz 1991). In this
test, the subject must touch a set of circles
with numbers on the computer screen in
numerical order as quickly as possible. Then
the subject must touch circles with numbers
and letters on the computer screen, alternating
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Table 2. Comparison of health status at the beginning of the TOS epidemic between TOS patient participants and
TOS patient nonparticipants: study of long-term neurologic outcomes of TOS, Madrid, Spain, 1999.
Characteristic Patient participants Nonparticipants




Motor neuropathy (%) 27.5 19.5
Cramps (%) 43.8 32.9
Sensory neuropathy (%) 57.5 53.7
Myalgias (%) 88.8 89.0
All p-values were nonsignificant.
Table 3. Sociodemographic and other characteristics for TOS patients and referent population: study of
long-term neurologic outcomes of TOS patients, Madrid, Spain, 1999.
Variable TOS patients Referent group
Age, median (10th–90th percentiles) 50.5 (25.0–59.0) 48.0 (24.0–59.0)
BMI, median (10th–90th percentiles) 25.9 (9.6–30.8) 25.1 (20.5–30.7)
K-BIT score, median (10th–90th percentiles) 99.5 (82.5–119.5) 101.5 (85.5–115)
Sex, no. (%)
Male 28 (35.0) 27 (34.2)
Female 52 (65.0) 52 (65.8)
Work situation,a no. (%) 61 (76.3) 60 (75.9)
Educational level,b no. (%) 27 (33.7) 19 (24.0)
Marital status,c no. (%) 56 (70.0) 55 (69.6)
Habits, no. (%)
Alcohol 27 (33.7) 29 (36.7)
Current smokers 31 (38.7) 30 (38.0)
Drugs 3 (3.7) 1 (1.3)
aPercentage of active workers. bPercentage of people who are illiterate or who know how to read or write only.
cPercentage of married people.
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between numbers and letters (i.e., 1, A, 2, B,
etc.). The preferred summary measures are the
latency to complete the set of numbers
(sequence A latency) and the numbers and let-
ters (sequence B latency). 
The auditory digit span test measures
attention and short-term memory. It consists
of auditory presentation of sequences of single
digits with the participant required to press
numbered keys on the computer screen in
order to represent the sequence. Increasingly
longer sequences are presented until the sub-
ject makes mistakes on two trials at a given
span length. Then digit sequences are pre-
sented, and the subject must press the num-
bered keys in reverse order from their auditory
presentation. The test continues until incor-
rect responses are given on two trials at a given
span length. The longest sequences forward
and backward answered correctly are the sum-
mary measures for this test. 
The visual span test is a visual analog to
the digit span test. Large blocks visible on
the computer screen are highlighted in a
temporal sequence. The subject must repro-
duce each sequence by touching the blocks
on the screen. Longer sequences are pre-
sented until two errors are made at a given
span length. A “backward” condition in
which the subject must reproduce the
sequence in reverse order is also adminis-
tered. Patients were asked about their famil-
iarity with video games, and self-reported
effort [Tryhard; a categorical appraisal of the
difficulty perceived when performing the
test; range: 0 (no difficulty) to 4 (maximum
difficulty)] in performing neurobehavioral
tests in order to assess their dexterity as con-
founding variables.
The Programa Integrado de Exploracion
Neuropsicologica [Integrated Program of
Neuropsychologic Examination (PIEN);
Peña-Casanova 1990] is a manual test to
assess a learning task with delayed recall; the
PIEN is used to evaluate a number of learn-
ing and memory parameters (acquisition, rate
of learning, interference, and delayed recall).
The vocabulary portion of the Kaufman Brief
Intelligence Test (K-BIT), Spanish version
(Kaufman and Kaufman 1996), was given to
measure vocabulary ability. The number of
correct items can be used as an index of
native intellectual ability that is resistant to
the effect of neurotoxicants, for “adjusting”
the other neurobehavioral outcome variables
in regression analyses.
All data for standing stability, heart rate
variability, NES2, and NES3 were written
directly to computer disk files. Special-pur-
pose data summary programs reduced these
raw data to produce summary measures for
each test. The questionnaire and manually
administered neurobehavioral testing data
were entered into database files for analysis.
Statistical Methods
The frequencies of currently reported neuro-
logic symptoms were stratified by case and ref-
erent group. Given that women have had a
poorer prognosis than men (Abaitua et al.
1998; Posada de la Paz et al. 1999), the statisti-
cal analyses were focused first on the overall
group and then stratified by sex. Median and
10th percentile/90th percentile were used on
all examiner-administered manual, neuro-
psychologic, and heart rate variability tests.
Associations between the case and referent
groups and the neurobehavioral and neuro-
physiologic outcomes of interest were exam-
ined. The difference in median test scores
between cases and referents was tested with
nonparametric tests (Wilcoxon test). The
severity of neurologic findings in TOS
patients was assessed using the following cri-
teria as a reference measure (gold standard):
in those quantitative tests in which a higher
score indicates better performance, we have
considered a pathologic outcome for TOS
patients to be values less than the 10th per-
centile of referent group values; in those tests
in which a higher score indicates poorer per-
formance, we have considered a pathologic
outcome for TOS patients to be values greater
than the 90th percentile of the referent
group values.
Environmental Health Perspectives • VOLUME 111 | NUMBER 10 | August 2003 1329
Table 4. Causes for specific exclusions and number of participants who completed each test: study of
long-term neurologic outcomes of TOS patients, Madrid, Spain, 1999.
TOS patients (n = 80) Referent group (n = 81)
Reason for exclusion Excluded Accepted Excluded Accepted
Age (< 18, > 65 years) 0 80 2 79
PNS
Motor examinations (cast right hand, broken left wrist, 2 78 2 77
torn long flexor right hand, surgery left wrist)
Sensory examinations 0 80 0 80
ANS
Coding error, medication use that could interfere with 11 69 10 69
testing (e.g., beta blockers, calcium antagonists, 
bronchodilators, antidepressants)
CNS
NES2 test (visual problems) 4 76 2 77
NES3 test (functionally illiterate, visual problems) 6 74 6 73
Grooved pegboard (visual problems) 11 69 5 74
Table 5. Distribution of neurologic symptoms by sex in TOS patients and referent group, study of long-term
neurologic outcomes of TOS patients, Madrid, Spain, 1999.
Symptoms by sex TOS patients Referent group OR (95% CI) p-Value
Males
CNS
Sleep trouble 10 2 6.94 (1.53–31.40) 0.01
Headache 7 3 2.67 (0.62–11.40) NS
Memory Loss 9 1 12.31 (2.00–75.76) 0.003
Poor coordination 1 0 3.00 (0.18–76.90) NS
PNS
Motor symptoms
Myalgias 10 4 6.94 (1.54–31.40) 0.01
Myoclonias 3 0 7.55 (0.37–153.0) NS
Muscle spasms 11 1 16.82 (1.98–142.0) 0.002
Strength loss 7 4 4.16 (0.84–20.66) NS
Sensory symptoms
Numbness 8 1 10.40 (1.62–66.71) 0.01
Paresthesias 12 2 9.37 (2.16–40.66) 0.003
Hypoesthesias 3 1 3.12 (0.32–29.50) NS
Females
CNS
Sleep trouble 22 9 1.65 (0.73–3.69) NS
Headache 27 13 3.24 (1.42–7.36) 0.005
Memory loss 21 11 2.52 (1.07–5.95) 0.03
Poor coordination 4 1 4.26 (0.46–39.54) NS
PNS
Motor symptoms
Myalgias 25 9 4.44 (1.83–10.79) 0.001
Myoclonias 19 1 30.03 (6.77–133.16) 0.001
Muscle spasms 26 1 53.08 (6.79–414.8) 0.001
Strength loss 19 7 3.76 (1.41–10.05) 0.006
Sensory symptoms
Numbness 27 5 10.15 (3.82–26.95) 0.001
Paresthesias 26 10 4.10 (1.73–9.86) 0.001
Hypoesthesias 13 4 4.00 (1.27–12.58) 0.020
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; NS, not significant.
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Subsequently, stepwise backward elimina-
tion multiple linear regression models were
fitted separately to each of the neurobehav-
ioral test score variables to control for poten-
tially confounding effects of important
covariates of the neurologic and neurobehav-
ioral outcomes in this population. The initial
set of covariates for the PNS outcomes
included age, sex, height, and body mass
index (BMI). The set of potential covariates
of CNS function were age, sex, education,
K-BIT score, experience in using video
games, and an index of self-reported effort
(Tryhard) when performing the tests (both
coded 1–4). The exposure group variable was
forced into all the backward elimination step-
wise regression models. Potential covariates
were eliminated until only the variables
related at the p < 0.05 level to the outcome
variable remained in the model. Results of
these analyses are presented in terms of the
standardized regression coefficients of the
variables remaining in the models. All statisti-
cal analyses were performed with SAS statisti-
cal software, version 6.12 for Windows (SAS
Institute 1989).
Results
Of the 160 TOS patients for which telephone
contact was attempted using the randomized
list of TOS patients in Alcorcón, 13 did not
meet the inclusion criteria and 67 refused or
were otherwise unable to participate, for an
overall participation rate of 54.4% (80 of 147)
of eligible participants contacted (Table 1).
We found no difference between TOS case
participants and TOS patients who refused
to participate in terms of neurologic symp-
toms at the time the epidemic began (“first
years since the outbreak,” checked with the
REVCEN, the official TOS morbidity reg-
istry) (Table 2). Table 3 shows the sociode-
mographic characteristics of the TOS case
patients and the referent group. No signifi-
cant differences were found between the two
groups in terms of age, sex, BMI, work sta-
tus, educational level, or tobacco, alcohol,
and drug consumption. Table 4 shows the
number of participants in each group who
were excluded from the final analyses for spe-
cific neurologic tests but who were included
in all other tests analyzed. We excluded two
of the original 81 referent group participants
because they did not meet the age criteria.
Thus, 79 participants were included as the
final referent group.
Symptoms and neurologic examination.
The percentage of some neurologic symptoms
was significantly higher in women than in
men in TOS patients: headache, 51.9% ver-
sus 25%; myoclonias, 38.5% versus 10.7%;
and numbness, 51.9% versus 28.6%, respec-
tively. We found statistically significant differ-
ences between the TOS patients and the
referent group for myoclonias, muscle spasms,
numbness, loss of strength, hypoesthesias,
paresthesias, poor coordination, headache,
trouble sleeping, and memory loss. After
stratifying by sex, we found that the overall
results were driven primarily by the effects in
women. Table 5 shows the distribution of
neurologic symptoms referred by the partici-
pants between TOS patients and the referent
group stratified by sex. These differences
between the TOS and referent groups were
greater in women > 35 years of age except for
trouble sleeping, which did not change when
it was stratified for the same variables. For
men, however, these differences disappeared
for the following variables: headache, poor
coordination, myoclonias, strength loss, and
hypoesthesias.
Unlike reported neurologic symptoms, the
standard clinical neurologic examinations
made by experienced neurologists did not
show differences between the TOS and refer-
ent groups except for an increase in pain in the
upper limbs and diminished superficial sensa-
tion in the lower limbs, although five TOS
patients did show a minor loss of strength
against external resistance (scored as 4/5).
Quantitative neurologic examination.
Table 6 shows the results of the specific quanti-
tative neurologic tests. For the six measures of
strength, between 28.2% and 35.9% of the
TOS patients had a strength lower than the
lowest 10th percentile of the referent group.
Of the four measures of vibratory sensation,
between 13.8% and 22.5% of all TOS patients
had a vibratory threshold greater than the 90th
percentile of the referent group in at least one
of the variables measured. Among the tests
used to assess cognitive function, we found
that three of them showed that more than
20% of TOS patients were over the 90th per-
centile of the referent group: simple reaction
time latency, sequence B latency, and digital
symbol latency.
When the analysis was stratified by sex,
most of these percentages were increased in
female TOS patients and ranged from 38% to
48% for strength measurements, from 19.2%
to 36.5% for vibratory sensation, and from
27.9% to 30.2% for the aforementioned
cognitive tests.
When we analyzed the effect of age by sex,
women between 35 and 55 years of age
showed the poorest strength scores. In tests of
sequence latency and digit symbol latency,
used for assessment of attention, mental con-
centration, and coding difficulty, latencies
greater than the 90th percentile of the referent
group were found in 14% of all women and
27.9% of all women > 55 years of age. The
simple reaction time increased with age. This
percentage ran from 30.2% for all women to
41.7% for women > 55 years of age.
Table 7 shows the median scores for the
neurologic and neurobehavioral outcomes in
both the TOS and referent groups. In all
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Table 6. Quantitative neurologic tests: percentage of all TOS patients, female TOS patients, and females in
two age strata, who fall below the 10th percentile or above the 90th percentile compared with the refer-
ence group in the study of long-term neurologic outcomes of TOS patients, Madrid, Spain, 1999.
Females
TOS patients Both sexes All females > 35 to < 55 years > 55 years
Motor strength evaluation
Distal strength preferred hand 29.5 40.0 36.8 47.1
Distal strength nonpreferred hand 30.8 46.0 52.6 47.1
Lateral pinch preferred hand 28.2 42.0 52.6 47.1
Lateral pinch nonpreferred hand 34.6 42.0 57.9 41.2
Palmar pinch preferred hand 35.9 48.0 57.9 35.3
Palmar pinch nonpreferred hand 32.1 38.0 68.4 41.2
Grooved pegboard preferred hand 21.2 18.0 25.0 27.3
Grooved pegboard nonpreferred hand 19.7 21.0 25.0 27.3
Finger tapping nonpreferred hand 15.0 23.1 31.3 36.4
Finger tapping left/right 12.0 15.4 18.8 9.1
Hand–eye coordination 7.6 5.1 6.3 9.1
Vibratory sensation
Preferred hand 18.8 26.9 10.5 36.8
Nonpreferred hand 22.5 36.5 31.6 63.2
Preferred foot 17.5 19.2 31.6 15.8
Nonpreferred foot 13.8 28.8 36.8 36.8
Standing steadiness
Eyes open 11.3 19.2 10.5 21.1
Eyes closed 13.3 23.1 26.3 31.6
Cognitive
Sequence A latency 10.0 14.0 11.8 16.7
Sequence B latency 25.4 27.9 0.0 16.7
Digital symbols latency 20.9 27.9 29.4 0.0
Auditory digit span forward 9.0 11.6 0.0 0.0
Auditory digit span backward 14.9 14 17.6 0.0
Visual span forward 14.9 0.0 0.0 0.0
Visual span backward 0.0 16.3 0.0 0.0
Simple reaction time 20.9 30.2 35.3 41.7
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measures used, TOS patients performed more
poorly than the referent group, although the
results were not statistically significant in 13
of 27 tests. Statistically significant differences
were found between the TOS patients and
the referent group in the results of peripheral
nerve function tests such as the median of the
distal strength, lateral pinch and palmar pinch
of the hands, and vibrotactile thresholds.
Electrocardiographic R–R intervals are
somewhat variable at rest and more variable
during deep breathing in normal individuals.
Autonomic neuropathy can lead to reduced
impact of deep breathing on R–R interval
variability. The median coefficient of varia-
tion of R–R intervals at rest was 3.1% in both
groups, whereas during deep breathing the
median coefficient of variation was statisti-
cally significantly lower in the TOS group
(5.25%) than in the referent group (7.3%,
p = 0.007).
The results of the standing steadiness test,
a quantitative analog to the clinical Romberg
test, with eyes open and eyes closed was simi-
lar for both the TOS and referent groups.
Results of tests of motor quickness and coor-
dination (grooved pegboard, finger tapping,
and hand–eye coordination) were also similar
for both the referent and TOS groups.
TOS patients, however, had poorer results
on five of the eight cognitive functions tested.
Of the five cognitive function tests, the largest
differences between the TOS group and the
referent group were found for the sequence B
test, the digit symbol test, and the auditory
digit span test.
Table 8, like Table 7, shows the median
scores for the neurologic and neurobehavioral
outcomes in both the TOS and referent
groups; however, in Table 8 the results are
analyzed only for the female participants of
both groups. These results show more dra-
matic differences than those of all subjects
together.
Multivariate analysis. To control for
potential confounding, all outcome variables
and first-order interaction variables were ana-
lyzed by stepwise backward elimination mul-
tiple linear regression models. Table 9 shows
the standardized regression coefficients from
these models. Anxiety, depression, and PIEN
score were introduced as independent vari-
ables in the models, although these variables
did not remain in any of the final models,
except for anxiety, which remained in the
reverse auditory digit backward span model.
In these models, TOS patients showed
poorer performance than the referent group
in five of the six variables used to measure
distal strength. Age, sex, BMI, and the inter-
action variables sex–case and age–case were
retained in the final model. Standing steadi-
ness, with eyes open as well as with eyes
closed, was not associated with illness even
after adjusting for sex and BMI. Regardless of
statistical significance, the estimated effect of
being in the exposed group was positive for 9
of the 12 PNS outcomes analyzed. The total
variance accounted for by the multiple
regression models of PNS outcomes varied
widely from an R2 = 0.10 for standing steadi-
ness with eyes open to an R2 = 0.71 for distal
strength of the dominant hand.
In the analysis of the ANS test results,
independent variables for tobacco, alcohol,
and drug use were entered initially, although
none of these remained in the model.
Analysis of the cognitive testing, after con-
trolling for covariates, showed a statistically
significant relationship between poor perfor-
mance on the sequence B test, the digit sym-
bol test, the reverse auditory digit test, and
simple reaction time test, and risk of being a
TOS case patient. The K-BIT, which mea-
sures vocabulary ability, was an important
covariate for all cognitive outcomes. Age, sex,
familiarity with video games, and self-reported
effort (Tryhard) in performing the tests, as
well as some interaction variables such as
age–K-BIT and K-BIT–Tryhard, were signifi-
cantly related to some of the cognitive out-
comes. R2 varied between 0.20 and 0.70. No
exposure group differences were statistically
significant for tests of coordination.
Discussion
This study of TOS patients reports the first
quantitative evidence of the existence of a
neurologic deficit that has persisted for 18
years after the intoxication. These findings are
very important because in all of the TOS case
series published (Martin Alvarez et al. 2000;
Philen and Posada 1993), as well as in the
experience of the physicians who work with
these patients, neurologic symptoms have
been a major clinical complaint. However, in
many patients it had not been possible to
demonstrate the existence of real neurologic
lesions because of lack of sensitivity of the
clinical neurologic examination. Additionally,
clinicians often decided against a muscle or
nerve biopsy because no effective treatment is
available. On some occasions TOS patients
have been stigmatized with other diagnoses
such as depression, anxiety syndrome, or
neurosis.
We found that TOS-affected participants
consistently reported more symptoms than a
referent group matched by sex and age, a
finding that has been suspected but not pre-
viously documented. Although the frequen-
cies of neurologic symptoms in the TOS
group were very high, no clinically relevant
abnormalities were observed in the physical
neurologic examinations performed by either
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Table 7. Quantitative neurologic measures of TOS patients and reference subjects in the study of long-
term neurologic outcomes of TOS patients, Madrid, Spain, 1999.
TOS patients Referent group
Neurologic test Median (10th–90th percentiles) Median (10th–90th percentiles) p-Value
Motor
Distal strength preferred hand 24.8 (10.7–45.3) 28.3 (18.3–46.0) 0.05
Distal strength nonpreferred hand 22.7 (8.3–44.2) 26.0 (18.0–43.0) 0.03
Lateral pinch preferred hand 7.2 (2.8–11.5) 8.0 (5.8–11.7) 0.05
Lateral pinch nonpreferred hand 6.3 (2.7–10.7) 7.3 (5.3–10.8) 0.03
Palmar pinch preferred hand 6.8 (2.8–11.2) 7.8 (5.7–11.2) 0.01
Palmar pinch nonpreferred hand 6.3 (2.7–10–7) 7.2 (5.2–10.2) 0.01
Finger tapping nonpreferred hand 122.5 (80.0–148.0) 123.0 (99.0–153.0) NS
Finger tapping left/right 157.0 (103.0–217.0) 168.0 (118.0–225.0) NS
Hand–eye coordination 2.3 (1.7–2.9) 2.3 (1.8–2.8) NS
Grooved pegboard preferred hand 64.0 (51.0–87.0) 61.5 (52.0–76.0) NS
Grooved pegboard nonpreferred hand 70.5 (55.0–100.0) 68.0 (58.0–87.0) NS
Vibratory sensation
Preferred hand 0.44 (0.11–0.83) 0.39 (0.05–0.64) NS
Nonpreferred hand 0.37 (0.08–0.85) 0.27 (0.04–0.57) 0.004
Preferred foot 0.98 (0.62–1.65) 0.89 (0.53–1.51) 0.05
Nonpreferred foot 0.98 (0.56–1.72) 0.89 (0.54–1.56) NS
Standing steadiness
Eyes open 1.68 (1.39–2.01) 1.65 (1.47–1.89) NS
Eyes closed 1.86 (1.59–2.39) 1.87 (1.60–2.34) NS
Cognitive
Sequence A latency 24.0 (16.5–39.5) 21.6 (15.3–35.9) NS
Sequence B latency 48.2 (29.4–107) 39.4 (25.9–86.2) 0.002
Digital symbol latency 102.6 (74.5–180) 89.8 (72.6–137) 0.04
Auditory digit span forward 5.0 (4–7) 6.0 (4–7) 0.04
Auditory digit backward span 4.0 (2–5) 4.0 (3–6) 0.008
Visual span forward 5.0 (3–6) 5.0 (4–6) 0.04
Visual span backward 4.0 (3–5) 4.0 (3–6) NS
Simple reaction time 285.0 (233.0–432.0) 276.6 (232.0–349.0) NS
ANS
CV of R–R (rest) 3.2 (1.6–6.3) 3.0 (1.8–6.6) NS
CV of R–R (deep breathing) 5.45 (2.2–13.2) 7.0 (3.4–14.1) 0.02
Abbreviation: CV, coefficient of variation; NS, not significant.
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of the two neurologists who examined the
study participants.
In the present study, we used quantitative
neurologic techniques originally developed to
identify workers with neurologic lesions result-
ing from occupational exposures to assess neu-
rologic signs and symptoms of a sample of
TOS patients. These techniques have already
been applied successfully in the study of other
diseases and environmental exposures, such as
EMS (Sullivan et al. 1996), epidemic neu-
ropathy in Cuba (Cuba Neuropathy Field
Investigation Team 1995), and people
exposed to lead (Stokes et al. 1998). This is the
first study of TOS patients to use quantitative
neurologic techniques to study the differences
between quantitative and objective neurologic
measures and the relationship of these measures
to reported symptoms. The results of this quan-
titative neurologic testing suggest that an addi-
tional evaluation of TOS patients beyond the
standard clinical assessments may be needed to
detect the adverse consequences of exposure.
In evaluating the results from the quantita-
tive neurologic examinations, we used the
10th and 90th percentiles of each measure
taken in the referent population to calculate
the percentage of TOS patients who had
scores that were less than or more than these
thresholds as well as the comparison among
medians of each test performed. The ANS
tests showed no substantial differences
between the TOS and referent groups except
for a coefficient that measured the change in
heart rate between resting and deep breathing,
suggesting less autonomic reactivity in the
TOS group. Most of the PNS tests showed
significantly worse performance in the TOS
group than in the referent group. The quanti-
tative neurologic tests performed in this study
demonstrated a clear motor and sensory deficit
in TOS patients, most likely a result of the
original neuropathy caused by TOS. Although
some participants partially recovered from the
original neuropathy, some residual deficit was
still present and measurable. These sequelae
were more important in women, showing a
more severe motor deficit in the 35–55-year-
old group and lessened vibratory sensation
among older women of the TOS group. These
findings are congruent with observations in
the TOS cohort that, at the beginning of the
epidemic, young women would have had a
poor prognosis (Posada de la Paz et al. 1999).
Although distal sensation loss is a frequent
finding in older people, TOS-affected women
showed poorer results than did the referent
group adjusted by age.
In order to properly complete the standing
steadiness test, it is necessary that the vestibular,
vision, and proprioceptive systems and the cen-
tral coordination of motor responses are not
damaged. Considering that these systems are
very sensitive, any neurologic disorder might
have been detected. However, no significant
differences were found.
The high proportion of CNS abnormali-
ties observed among the TOS patients are the
first sign of possible CNS lesions related to
TOS. This is the first study in which a likely
memory disorder and less response to stimu-
lus have been quantified in these patients.
Although some neuronal abnormalities, such
as vacuolization, have been seen in the
necropsies of some TOS patients, a CNS
lesion was never clearly established (Ricoy et
al. 1983). In addition, although 1% of the
total cohort developed brain edema during
the acute phase, and memory loss has been
one of the major complaints of this cohort
(Portera-Sanchez and Posada de la Paz 2000),
actual CNS lesions have never been identified
in TOS patients using an objective test.
Although our study does not prove the exis-
tence of a CNS lesion, a careful follow-up of a
group of patients should be done in order to
rule out that possibility.
The Alcorcón locality was selected for this
study primarily for logistical purposes; the
neighborhood has a new, modern hospital that
allowed us to use its facilities, and the area has
a large enough population of TOS-affected
people from which to sample. Past studies
have not shown any major differences between
the population of Alcorcón and other TOS-
affected populations (Gomez et al. 1998).
Although the response rate was 54.4%,
we did not find any significant differences
between TOS patients who participated and
TOS patients who refused to participate in
terms of age, sex, or main features of the dis-
ease checked with the official morbidity reg-
istry (REVCEN) (Kilbourne et al. 1992). The
referent group cannot be considered a real
control group because our goal was not to
carry out a case–control study but to obtain
some reference data from people from the
same locality who were not affected and to
adjust these data by age and sex. (A referent
case only uses the controls as a population ref-
erence pattern; it does not intend to estimate
the relative risk but provides a normality pat-
tern of such population from which cases
have been recruited.) In our opinion, and
despite the fact that the referent group does
not come from a simple random sampling of
the Alcorcón locality, the results could be
biased. The absence of randomization could
have selected a population subgroup more
eager to collaborate for causes related to their
health status. Adjustment was made using
other variables such as age, sex, education
level, and cognitive basal tests in order to
reduce this potential bias.
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Table 8. Quantitative neurologic measures of TOS patients and reference subjects in the study of long-
term neurologic outcomes of TOS patients, Madrid, Spain, 1999.
TOS patients Referent group
Neurologic test Median (10th–90th percentiles) Median (10th–90th percentiles) p-Value
Motor
Distal strength preferred hand 19.5 (8.8–26.5) 25.0 (16.5–31.0) 0.0001
Distal strength nonpreferred hand 18.3 (6.0–25.0) 23.3 (17.2–29.0) 0.0001
Lateral pinch preferred hand 5.8 (2.3–8.4) 7.2 (5.4–8.3) 0.0003
Lateral pinch nonpreferred hand 5.1 (1.9–7.8) 6.7 (4.7–8.0) 0.0001
Palmar pinch preferred hand 5.4 (2.2–8.0) 7. (5.3–8.4) 0.0001
Palmar pinch nonpreferred hand 5.1 (2.1–7.0) 6.4 (5.0–7.7) 0.0002
Finger tapping nonpreferred hand 109.5 (73.0–137.0) 112.0 (98.5–148.0) NS
Finger tapping left/right 138.0 (92.0–200.0) 159.5 (115.0–219.0) 0.01
Hand–eye coordination 2.4 (1.7–2.9) 2.4 (1.8–2.9) NS
Grooved pegboard preferred hand 62.0 (51.0–87.0) 63.0 (53.0–76.0) NS
Grooved pegboard nonpreferred hand 68.0 (57.0–98.0) 70.0 (58–87.0) NS
Vibratory sensation
Preferred hand 0.5 (0.2–0.8) 0.4 (0.1–0.6) 0.04
Nonpreferred hand 0.4 (0.1–0.8) 0.3 (0.01–0.5) 0.004
Preferred foot 1.0 (0.6–1.6) 0.9 (0.6–1.4) 0.02
Nonpreferred foot 1.0 (0.6–1.6) 0.9 (0.6–1.3) 0.02
Standing steadiness
Eyes open 1.9 (1.6–2.5) 1.9 (1.5–2.2) NS
Eyes closed 1.7 (1.4–2.1) 1.6 (1.5–1.9) NS
Cognitive
Sequence A latency 25.4 (17.6–39.9) 21.2 (15.3–35.9) 0.03
Sequence B latency 58.1 (34.7–108.4) 39.6 (25.8–93.0) 0.003
Digital symbol latency 107.2 (79.1–180) 86.5 (72.6–163.3) 0.01
Auditory digit span forward 5.0 (3–6) 6.0 (4–7) 0.005
Auditory digit span backward 4.0 (2–5) 4.0 (3–6) 0.02
Visual span forward 5.0 (3–6) 5.0 (3–6) NS
Visual span backward 4.0 (3–5) 4.0 (4–6) 0.01
Simple reaction time 06.2 (238–472.4) 281.7 (236.6–361.0) 0.02
ANS
CV of R–R (rest) 3.05 (1.6–6.3) 3.1 (1.8–6.6) NS
CV of R–R (deep breathing) 5.25 (2.1–11.6) 7.3 (3.4–14.1) 0.007
Abbreviation: CV, coefficient of variation; NS, not significant.
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Because of specific individual factors, such
as recent hand trauma or surgery, a few patients
were excluded from certain tests. We do not
believe that small differences in the number of
cases included in each examination contributed
to any significant bias in the final result.
This and other TOS-related research will
continue to provide a basis for future research
in groups of people affected with similar dis-
eases, such as EMS and other neurologic syn-
dromes with symptoms that are hard to
quantify or document. Although these tests
may not be useful for follow-up or diagnosis
for an individual patient, they can be used as a
screening tool for a population of patients with
the same disease, or as a tool for follow-up to
measure the improvement or deterioration
over time of neurologic signs and symptoms in
a specific group. 
In summary, the TOS epidemic is not
only an informative episode of environmental
illness in modern medicine that merits follow-
up of all its aspects, including etiology, clinical
evolution, chemical toxicology, and pathogen-
esis, but it is also an episode from which
researchers will continue to learn many things
that will be applicable to similar problems in
the future.
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Table 9. Standardized regression coefficients from stepwise regression models for neurologic and neurobehavioral outcomes: study of long-term neurologic out-
comes of TOS patients, Madrid, Spain, 1999.
Video Interaction
Dependent variable TOS Age Sex BMI Education games Tryhard K-BIT Anxiety variablesa R2
PNS test
Motor evaluation
Distal strength preferred hand 0.35* — –0.19 — — — — — — 1 0.71
Distal strength nonpreferred hand –0.12* — –0.63 — — — — — — — 0.65
Lateral pinch preferred hand –0.17* –0.21 –0.69 0.16 — — — — — — 0.58
Lateral pinch nonpreferred hand 0.35 0.33 –0.52 0.16 — — — — — 1 0.58
Palmar pinch preferred hand –0.23** –0.22 –0.65 — — — — — — — 0.56
Palmar pinch nonpreferred hand –0.21** –0.22 –0.67 0.12 — — — — — — 0.57
Simple reaction timeb 0.15* 0.29 0.27 — — — — — — — 0.20
Grooved pegboard preferred hand 0.07 2.31 –1.31 — — — — 0.42 — 2 0.40
Grooved pegboard nonpreferred hand 0.06 0.32 –0.16 — –0.22 — — 0.72 — 1 0.36
Finger tapping nonpreferred hand –0.05 –0.20 0.07 — 0.20 — — — — 1 0.54
Finger tapping left/right –0.06 –0.37 — — 0.27 0.17 — — — — 0.57
Hand–eye coordination –0.08 0.36 0.17 — 0.23 — — –0.20 — — 0.48
Standing steadiness
Eyes closedb 0.01 0.01 — –0.30 — — — — — — 0.30
Eyes openb –0.02 0.01 — –0.02 — — — — — — 0.10
Sensory evaluation
Vibration threshold preferred handb –0.88* 0.49 0.13 –0.59 — — — — — 1 0.32
Vibration threshold nonpreferred handb –1.19* 0.39 — –0.72 — — — — — 1 0.36
Vibration threshold preferred footb 0.17** 1.19 0.68 — — — — — — 1 0.35
Vibration threshold nonpreferred footb 0.13* 0.61 — — — — — — — — 0.31
Electrophysiological (ANS)
CV of R–R interval (deep breathing) –0.09 –0.62 — — — — — — — — 0.40
CV of R–R interval (normal breathing) 0.10 –0.44 — — — — — — — — 0.19
Cognitive (CNS)
Sequence A latencyb 0.08 2.18 — — — — — 0.52 — 1 0.46
Sequence B latencyb 0.16** 1.78 — — — — — 0.15 — 1 0.63
Digital symbol latencyb 0.94** 2.50 0.11 — — — — 0.67 — 2 0.70
Auditory digit span forward –0.08 — — — — 0.20 — 0.48 — — 0.34
Auditory digit span backward –0.13* –0.25 — — 0.18 — — 0.26 –0.15 — 0.41
Visual span forward –0.13 –0.37 — — — — — 0.24 — — 0.28
Visual span backward –0.09 –0.50 — — — — –0.15 0.20 — — 0.33
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aNumber of first order interaction variables that remain in the model. bScores inverted so that higher score indicates better performance. *p < 0.05; **p < 0.01.
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